Hiroyuki Shibata

ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 9

Top Venues

Japanese journal of clinical oncology

Cancer science

International journal of clinical oncology

Pathology international

Akita University

Tohoku University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Akita University Feb 01 2009

Japan

Professor :: Department of Clinical Oncology

Tohoku University

Japan

Associate Professor :: Department of Clinical Oncology

Tohoku University Hospital

Japan

Lecturer :: Department of Clinical Oncology

Tohoku University Apr 01 1996

Japan

Assistant Professor :: Department of Clinical Oncology of IDAC

Cancer Institute Oct 01 1991 - Mar 31 1996

Japan

Attending Associate :: Department of Cell Biology

Education History

Tohoku University Apr 01 1987 - Mar 31 1991

Japan

PHD :: Department of Cancer Chemotherapy

Publications

Risa Akahira, Koji Fukuda, Kazuhiro Shimazu, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Hiroshi Nanjyo, Hiroyuki Shibata
Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor. Japanese journal of clinical oncology (2023)
Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Katsuharu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. Cancer medicine (2022)
Miki Kiyomiya, Koji Fukuda, Kazuhiro Shimazu, Taichi Yoshida, Daiki Taguchi, Hanae Shinozaki, Hiroshi Nanjyo, Hiroyuki Shibata
Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab. Japanese journal of clinical oncology (2022)
Takashi Maruyama, Shuhei Kobayashi, Hiroyuki Shibata, WanJun Chen, Yuji Owada
Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy. Cancer science 112 (12) (2021)
Risako Sekine, Kazuhiro Shimazu, Daisuke Nakano, Tatsuro Yamaguchi, Yusato Suzuki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Katsunori Iijima, Hiroshi Nanjyo, Hiroyuki Shibata
A novel Lynch syndrome pedigree bearing germ-line MSH2 missense mutation c.1808A>T (Asp603Val). Japanese journal of clinical oncology (2021)
Yohei Yamamoto, Aki Nishijima-Matsunobu, Yuko Hiroshima, Katsuhiko Enomoto, Masahiro Inoue, Osamu Muto, Maya Suzuki, Hiroshi Nanjo, Hiroyuki Shibata, Yasufumi Omori
Two autopsy cases of desmoplastic small round cell tumor. Pathology international 70 (3) (2020)
Daiki Taguchi, Masahiro Inoue, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Kazuma Fujita, Hiroyuki Okuyama, Nobuhisa Matsuhashi, Akihito Tsuji, Kazuhiro Yoshida, Masatomo Miura, Hiroyuki Shibata
Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities. International journal of clinical oncology 25 (4) (2019)
Kazuhiro Shimazu, Masahiro Inoue, Shunsuke Sugiyama, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Yoshihiko Uehara, Sei Kuriyama, Masamitsu Tanaka, Masatomo Miura, Hiroshi Nanjyo, Yoshiharu Iwabuchi, Hiroyuki Shibata
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors. Cancer science 109 (10) (2018)
Taichi Yoshida, Daiki Taguchi, Koji Fukuda, Kazuhiro Shimazu, Masahiro Inoue, Katsunori Murata, Hiroyuki Shibata
Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution. International journal of clinical oncology 22 (2) (2016)

Hiroyuki Shibata.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroyuki Shibata